Spots Global Cancer Trial Database for trc105
Every month we try and update this database with for trc105 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) | NCT01090765 | Prostate Cancer Metastatic Cast... | TRC105 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| TRC105 for Recurrent Glioblastoma | NCT01778530 | Glioblastoma Mu... | TRC105 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) | NCT02664961 | Gestational Tro... Choriocarcinoma Placental Site ... Epithelioid Tro... | TRC105 Bevacizumab | 16 Years - 99 Years | Tracon Pharmaceuticals Inc. | |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | NCT02429843 | Lung Cancer | TRC105 | 19 Years - | University of Alabama at Birmingham | |
| Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | NCT01332721 | Adult Solid Tum... | TRC105 and Beva... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated | NCT01332721 | Adult Solid Tum... | TRC105 and Beva... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| TRC105 for Liver Cancer That Has Not Responded to Sorafenib | NCT01375569 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... | TRC105 | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma | NCT02979899 | Advanced Angios... | TRC105 Votrient | 12 Years - | Tracon Pharmaceuticals Inc. | |
| Trial of TRC105 and Sorafenib in Patients With HCC | NCT02560779 | Hepatocellular ... | Carotuximab (TR... Sorafenib | 18 Years - | Tracon Pharmaceuticals Inc. | |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | NCT02429843 | Lung Cancer | TRC105 | 19 Years - | University of Alabama at Birmingham | |
| Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer | NCT00582985 | Cancer Neoplasm Metast... | TRC105 chimeric... | 18 Years - | Tracon Pharmaceuticals Inc. | |
| TRC105 for Liver Cancer That Has Not Responded to Sorafenib | NCT01375569 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... | TRC105 | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC | NCT03780010 | Non Small Cell ... | TRC105 | 18 Years - | Tracon Pharmaceuticals Inc. | |
| TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma | NCT01328574 | Urothelial Carc... Ureteral Neopla... Ureter Cancer Neoplasm, Urete... Cancer of the U... | TRC105 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma | NCT02396511 | Choriocarcinoma | TRC105 Bevacizumab | 18 Years - | Tracon Pharmaceuticals Inc. | |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | NCT02429843 | Lung Cancer | TRC105 | 19 Years - | University of Alabama at Birmingham | |
| TRC105 for Recurrent Glioblastoma | NCT01778530 | Glioblastoma Mu... | TRC105 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sorafenib and TRC105 in Hepatocellular Cancer | NCT01306058 | Hepatoma Liver Neoplasms Adenoma, Liver ... Carcinoma, Hepa... Liver Neoplasms... | TRC 105 Sorafenib | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
